- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Dermavance ready to launch
Berwyn, Pa. - DermAvance Pharmaceuticals, a privately heldspecialty dermatology pharmaceutical company, has appointed KeithA. Greathouse as president and chief executive officer. The companyalso announced the launch of its first products, including Vivelif,a topical therapy to address visible signs of aging.
Berwyn, Pa. - DermAvance Pharmaceuticals, a privately held specialty dermatology pharmaceutical company, has appointed Keith A. Greathouse as president and chief executive officer. The company also announced the launch of its first products, including Vivelif, a topical therapy to address visible signs of aging.
Mr. Greathouse was formerly executive vice president for Sanofi-Aventis Dermatology (Dermik).
Related Videos
Recapping the Evolving Treatment Landscape for Atopic Dermatitis
Sunscreen Ingredients for UV and Visible Light Protection
The Solar Spectrum and Impact on Skin Health
Discussing Efficacy and Safety of JAK Inhibitors With Patients and Caregivers
Patient Considerations for Selecting Treatment for a 16-Year-Old Male With Severe Alopecia Areata
Future Directions for Pediatric Atopic Dermatitis Management and Research
New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors
The JAK-STAT Signaling Pathway and Its Role in Atopic Dermatitis
Selecting Systemic Therapy for Patients with Moderate to Severe Atopic Dermatitis
Pipeline Updates on the Horizon From Arcutis Biotherapeutics
Related Content
